COO at a glance
Cooper Companies (The) (COO, SEC CIK 711404) filed its latest 10-K annual report on December 5, 2025, a 10-Q quarterly report on September 9, 2026, an 8-K current report on September 9, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended October 31, 2025 (FY2025), Cooper Companies (The) (COO) reported revenue of $4.1 billion (up 5.1% from FY2024) and net income of $374.9 million. Diluted EPS was $1.87.
- The most recent insider open-market purchase reported on Form 4 was by Kurzius Lawrence Erik on September 16, 2026 of 10,000 shares at $54.93 per share.
- In the last 90 days, COO insiders reported 5 open-market purchases ($1.9M) and 0 open-market sales ($0) on Form 4, a net purchase of $1.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.1B
- +5.1% vs prior year
- Insiders · 90 days
- 5 buys · 0 sells
- Net +$1.9M
- Latest 8-K
- Sep 9, 2026
- Item 2.02 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Oct 31, 2025
Business Overview
- Core business model: global medical device company with two segments, CooperVision and CooperSurgical, focused on vision, fertility, and women’s health
- Expanded geographic reach, selling products in over 130 countries
- Positive impact on over 50 million lives annually reported
- Headquartered in San Ramon, California, emphasizing global leadership in medical devices
Management Discussion & Analysis
- Outlook optimistic on long-term contact lens and general health care market growth
- Risks and uncertainties acknowledged in global operating environment
Risk Factors
- Regulatory risk: FDA and NMPA approvals for MiSight 1 day lens to slow myopia progression in children aged 8-12, critical for market penetration in US, China, and Japan
- Macroeconomic exposure: 5% net sales growth in Americas and 8% in EMEA, driven by silicone hydrogel lenses, with revenue positively impacted by $16 million favorable foreign exchange in 2025
- Operational vulnerability: Inventory and long-lived asset write-offs and severance costs from workforce optimization initiatives negatively impacted gross margin and operating income in CooperSurgical in 2025
- Competitive risk: Market competition in contact lenses from products with advancing technology such as silicone hydrogel lenses (Biofinity, MyDay) and myopia management lenses
- Financial risk: High leverage with $2.456 billion borrowings against a $3.8 billion credit facility and $100 million interest expense, with $966 million authorized but unspent for share repurchases as of October 31, 2025
AI summary of the COO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jul 31, 2026
Management Discussion & Analysis
- No profitability, margin, or segment-performance figures disclosed
- Litigation contingencies subject to significant judgment and legal uncertainty
Risk Factors
- No material changes to risk factors from October 31, 2025 Form 10-K
- Carried-forward regulatory, legal and compliance risks unchanged from the 10-K
- Carried-forward operational, competitive and market risks unchanged from the 10-K
- Carried-forward liquidity, debt, currency and concentration risks unchanged from the 10-K
AI summary of the COO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q3 2026 results released September 9, 2026, covering the quarter ended July 31, 2026
- Detailed financial performance and management commentary contained in Exhibit 99.1
Item 8.01: Other Events
- Strategic review completed, signaling no immediate major portfolio or strategic transaction announcement
- Increased share repurchase authorization, supporting capital returns and potentially reducing shares outstanding
Item 8.01: Other Events
- $271.6M net litigation charge recorded in SG&A for recalled embryo culture media claims
- $324.1M accrued litigation liabilities, offset by $52.5M expected insurance recoveries
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q2 2026 results covered quarter ended April 30, 2026
- Press release issued June 4, 2026; detailed financial figures are in the attached exhibit
Item 7.01: Regulation FD Disclosure
- Press release announces Mr. Keel’s appointment
- Appointment details and potential leadership implications contained in Exhibit 99.1
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expansion from 9 to 10 directors effective July 1, 2026
- Paul Keel appointed director and Audit Committee member effective July 1, 2026
AI summaries of COO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for COO
Don't miss the next COO filing
- Alerts as it files. A push when COO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut COO, by share count.
- Ask anything. An AI agent that reads every COO filing and answers with sources.
COO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kurzius Lawrence Erik | Buy | Sep 16, 2026 | 10,000 | $54.93 |
| Kurzius Lawrence Erik | Buy | Sep 14, 2026 | 10,000 | $53.91 |
| Rosebrough Walter M Jr | Buy | Sep 14, 2026 | 3,000 | $54.29 |
| Rosebrough Walter M Jr | Buy | Sep 11, 2026 | 7,000 | $54.11 |
| Keel Paul A | Buy | Sep 11, 2026 | 4,701.015 | $53.18 |
| Keel Paul A | A | Jul 1, 2026 | 2,814 | - |
| Rivas Maria | M | Apr 1, 2026 | 3,322 | - |
| Jay Colleen | M | Apr 1, 2026 | 3,322 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.9B | $4.1B |
| Gross Profit | - | $2.6B | $2.7B |
| Operating Income | - | $705.7M | $682.9M |
| Net Income | - | $392.3M | $374.9M |
| Gross Margin | - | 66.6% | 65.5% |
| Op. Margin | - | 18.1% | 16.7% |
| Net Margin | - | 10.1% | 9.2% |
| Balance Sheet | |||
| Total Assets | $11.7B | $12.3B | $12.4B |
| Equity | $7.6B | $8.1B | $8.2B |
| ROE | - | 4.9% | 4.6% |
| Per Share | |||
| EPS | - | $1.96 | $1.87 |
| Cash Flow | |||
| Operating CF | - | $709.3M | $796.1M |
| CapEx | - | $421.2M | $362.4M |
Source: XBRL data in Cooper Companies (The) (COO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
COO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 10-Q | Sep 9, 2026 | Jul 31, 2026 | Analysis | |
| 4 | Jul 6, 2026 | - | - | - |
| 10-Q | Jun 5, 2026 | Apr 30, 2026 | Analysis | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Apr 21, 2026 | - | - | - |
| 8-K | Apr 8, 2026 | - | Analysis | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 10-Q | Mar 6, 2026 | Jan 31, 2026 | Analysis | |
| 8-K | Mar 5, 2026 | - | Analysis | - |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - |
Related Health Care companies
- BLCO · Bausch & Lomb CorpOphthalmic Goods
- EYE · National Vision Holdings, Inc.Ophthalmic Goods
- RXST · RxSight, Inc.Ophthalmic Goods
- STAA · STAAR SURGICAL COOphthalmic Goods
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
COO SEC filings: frequently asked questions
Are COO insiders buying or selling?
In the last 90 days, Cooper Companies (The) (COO) officers, directors and 10% owners reported 5 open-market purchases worth $1.9 million by 3 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was COO's revenue in fiscal year 2025?
For the fiscal year ended October 31, 2025 (FY2025), Cooper Companies (The) (COO) reported revenue of $4.1 billion (up 5.1% from FY2024) and net income of $374.9 million. Diluted EPS was $1.87. The figures come from the XBRL data in the 10-K.
What are the main risks in COO's latest 10-K?
In the 10-K filed December 5, 2025, Cooper Companies (The) (COO) flagged: Regulatory risk: FDA and NMPA approvals for MiSight 1 day lens to slow myopia progression in children aged 8-12, critical for market penetration in US, China, and Japan. Macroeconomic exposure: 5% net sales growth in Americas and 8% in EMEA, driven by silicone hydrogel lenses, with revenue positively impacted by $16 million favorable foreign exchange in 2025. (AI summary of the Risk Factors section.)
What did COO report in its latest 8-K?
Cooper Companies (The) (COO) filed an 8-K on September 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Fiscal Q3 2026 results released September 9, 2026, covering the quarter ended July 31, 2026.
What are the latest COO SEC filings?
Cooper Companies (The) (COO) filed its latest 10-K annual report on December 5, 2025, a 10-Q quarterly report on September 9, 2026, an 8-K current report on September 9, 2026 and a Form 4 insider filing on September 17, 2026.
What is COO's SEC CIK number?
Cooper Companies (The) (COO)'s SEC Central Index Key (CIK) is 711404. EDGAR lists every COO filing under that number.
Ask anything about COO
The research agent reads COO's filings, financials, insider trades and 13F holders, then answers with sources.